Novartis inks US$ 5.7 bn licensing deal with Monte Rosa for immune-related diseases; GSK, Lilly pledge more investments in US
In this week’s news, drugmakers continued to invest heavily in the US in order to avoid tariffs. GSK said it will invest ...